Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Company reports Q3 results, provides MS-325 regulatory update
December 12th, 2004
EPIX Pharmaceuticals, Inc., (EPIX), a developer of pharmaceuticals for magnetic resonance imaging (MRI), announced its financial results for the third quarter 2004 and provided an update on the regulatory status of the new drug application (NDA) for MS-325, the company's lead imaging pharmaceutical designed for magnetic resonance angiography (MRA). Financial highlights for the quarter ended September 30, 2004 included: 1) Net loss of $6.4 million, or $0.28 per share, in the third quarter of 2004 compared to a net loss of $3.4 million, or $0.17 per share, for the third quarter of 2003. 2) Revenues of $3.2 million in the third...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
